Novo Nordisk A/S - Articles of Association, April 2024
April 24, 2024 08:57 ET
|
Novo Nordisk A/S
Novo Nordisk's Articles of Association, April 2024
Attachment
Articles of Association 24 Apr 2024
...
Novo Nordisk A/S – Reduction of the share capital
April 24, 2024 08:48 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 24 April 2024 – At Novo Nordisk’s Annual General Meeting on 21 March 2024, it was decided to reduce the company’s B share capital from DKK 343,512,800 to DKK 339,012,800 by...
Global Diabetes Drugs Market to Witness an Upsurge in Growth by 2030, Examines DelveInsight | Key Companies in the Market - Sanofi, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Merck & Co., Novo Nordisk, Eli Lilly and Company, Biocon
April 23, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 23, 2024 (GLOBE NEWSWIRE) -- Global Diabetes Drugs Market to Witness an Upsurge in Growth by 2030, Examines DelveInsight | Key Companies in the Market - Sanofi, AstraZeneca,...
Novo Nordisk A/S - share repurchase programme
April 22, 2024 09:06 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 22 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
April 22, 2024 07:00 ET
|
SNIPR Biome
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase 1b/2a trial will evaluate SNIPR001 for the...
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
April 22, 2024 02:00 ET
|
SNIPR Biome
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase 1b/2a trial will evaluate SNIPR001 for the...
Global Peptide Synthesis Market Analysis and Outlook 2024: Competitive Analysis of Leading Market Players, Product Developments, Key Financial and Segmental Revenues
April 18, 2024 09:54 ET
|
Research and Markets
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Peptide Synthesis: Global Markets 2023-2028" report has been added to ResearchAndMarkets.com's offering. The global market for peptide synthesis is...
Global Pediatric Drugs And Vaccines Market Size To Exceed USD 265.5 Billion By 2033 | CAGR of 8.04%
April 17, 2024 15:30 ET
|
SPHERICAL INSIGHTS LLP
New York, United States, April 17, 2024 (GLOBE NEWSWIRE) -- The Global Pediatric Drugs and Vaccines Market Size is to Grow from USD 122.5 Billion in 2023 to USD 265.5 Billion by 2033, at a Compound...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
April 15, 2024 13:39 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 15 April 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
Novo Nordisk A/S - share repurchase programme
April 15, 2024 08:43 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 15 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...